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ABSTRACT 
 
Acyl CoA Binding Protein (ACBP) Gene Ablation Induces Pre-Implantation Embryonic 
Lethality in Mice. (December 2010) 
Danilo Landrock, Diplom (B.S. equivalent), Berlin, Germany 
Co-Chairs of Advisory Committee,    Dr. Ann B. Kier 
Dr. Friedhelm Schroeder 
 
Unique among the intracellular lipid binding proteins, acyl CoA binding protein (ACBP) 
exclusively binds long chain fatty acyl CoAs (LCFA-CoAs). To test if ACBP is an 
essential protein in mammals, the ACBP gene was ablated by homologous 
recombination in mice. While ACBP heterozygotes appeared phenotypically normal, 
intercrossing of the heterozygotes did not result in any live homozygous deficient (null) 
ACBP(-/-) pups. Heterozygous and wild type embryos were detected at all 
postimplantation stages, but no homozygous ACBP null embryos were obtained–
suggesting that an embryonic lethality occurred at a preimplantation stage of 
development, or that embryos never formed. While ACBP null embryos were not 
detected at any blastocyst stage, ACBP null embryos were detected at the morula (8-
cell), cleavage (2-cell), and zygote (1-cell) preimplantation stages. Two other LCFA-
CoA binding proteins, sterol carrier protein-2 (SCP-2) and sterol carrier protein-x (SCP-
x) were significantly upregulated at these stages. These findings demonstrate for the first 
time that ACBP is an essential protein required for embryonic development and its loss 
of function may be initially compensated by concomitant upregulation of two other 
iv 
LCFA-CoA binding proteins only at the earliest preimplantation stages. The fact that 
ACBP is the first known intracellular lipid binding protein whose deletion results in 
embryonic lethality suggests its vital importance in mammals.  
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NOMENCLATURE 
 
Acaca  Acetyl CoA carboxylase A 
Acacb  Acetyl CoA carboxylase B 
Acadl  Long Chain Acyl CoA Dehydrogenase 
ACBP  Acyl CoA Binding Protein 
Atp1b1 Na+, K+-ATPase (ATPase, Na+/K+ transporting beta 1 polypeptide) 
Atp2a2 Ca++-ATPase (endoplasmic reticulum) 
Capn2  m-Calpain 
CoA  Coenzyme A 
CPT1  Carnitine Palmitoyltransferase 1 
Dbi  Diazepam Binding Inhibitor 
DNA  Deoxyribonucleic acid 
dpc  Days post coitum 
EDTA  Ethylenediaminetetraacetic acid 
ES cells Embryonic Stemm Cells 
FABP1 Fatty Acid Binding Protein 1 (liver fatty acid binding protein, L-FABP) 
FABP2 Fatty Acid Binding Protein 2 (intestinal fatty acid binding protein,  
I-FABP) 
FABP3 Fatty Acid Binding Protein 3 (heart/muscle fatty acid binding protein,  
  H-FABP) 
FABP4 Fatty Acid Binding Protein 4 (adipocyte fatty acid binding protein,  
  A-FABP) 
vii 
FABP5 Fatty Acid Binding Protein 5 (epidermal/keratinocyte fatty acid binding 
protein, E-FABP) 
 
FABP6 Fatty Acid Binding Protein 6 (ileal fatty acid binding protein, Il-FABP) 
FABP7 Fatty Acid Binding Protein 7 (brain fatty acid binding protein, B-FABP) 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
Gck  Glucokinase (hexokinase 4) 
HCG  Human Chorionic Gonadotropin 
Hk1  Hexokinase 1 
Hk2  Hexokinase 2 
Hk3  Hexokinase 3 
Hmgcr  HMG-CoA reductase 
kDa  Kilo Dalton 
KSOM  Potassium Simplex Optimized Medium 
LCFA  Long Chain Fatty Acids 
LIF  Leukemia Inhibitory Factor 
Lipe  Hormone Sensitive Lipase 
PCR  Polymerase Chain Reaction 
PMEF  Primary Mouse Embryonic Fibroblasts 
PMSG  Pregnant Mare Serum Gonadotropin 
Prkaa2  Protein Kinase AMP activated α 2 catalytic subunit 
PPARα Peroxisome Proliferator Activated Receptor α 
PPARβ Peroxisome Proliferator Activated Recepto β 
PPARγ Peroxisome Proliferator Activated Receptor γ 
viii 
Q-rtPCR Quantitative Reverse Transcriptase Polymerase Chain Reaction 
RNA  Ribonucleic acid 
SCP-x  Sterol Carrier Protein x 
SCP-2  Sterol Carrier Protein 2 
SDS  Sodium Dodecyl Sulfate 
Slc25a4 Solute Carrier Family 25 member 4 (mitochondrial carrier, adenine 
nucleotide translocator) 
 
Slc25a5 Solute Carrier Family 25 member 5 (mitochondrial carrier, adenine 
nucleotide translocator) 
 
Slc25a13 Solute Carrier Family 25 member 13 (mitochondrial carrier, adenine 
nucleotide translocator) 
 
Slc25a20 Solute Carrier Family 25 member 20 (mitochondrial 
carnitine/acylcarnitine translocase) 
 
Slc25a31  Solute Carrier Family 25 member 31 (mitochondrial carrier, adenine 
nucleotide translocator) 
 
SREBP Sterol Regulatory Element Binding Protein 
Thrα  Thyroid hormone receptor α 
Thrβ  Thyroid hormone receptor β 
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INTRODUCTION AND LITERATURE REVIEW* 
Known Physiological Role of Acyl CoA Binding Protein 
Acyl CoA binding protein (ACBP), also known as diazepam binding inhibitor (DBI), is 
a soluble 10 kDa lipid binding protein ubiquitously expressed in all tissues of eukaryotic 
species examined (1, 2). ACBP expression differs significantly among cell types and is 
highly regulated by hormones (insulin, androgens). Via the ACBP promoter, ACBP 
expression is also determined by several nuclear transcription factors important in lipid 
and glucose metabolism: peroxisome proliferator-activated receptors (PPARs) -α and -γ 
as well as sterol regulatory element binding protein (SREBP) (3-7). Unique among the 
intracellular lipid protein families, ACBP exhibits very high affinity (<10nM Kds) and 
specificity exclusively for long chain fatty acyl CoAs (LCFA-CoAs) (8, 9).  LCFA-
CoAs are potent regulators of a wide variety of enzymes, signaling receptors, and 
nuclear regulatory proteins involved in fatty acid and glucose metabolism (1, 10-13). For 
example, LCFA-CoAs at very low concentration (Ki <50nM) inhibit acetyl CoA 
carboxylase (Acac), the key rate limiting enzyme of de novo fatty acid synthesis from 
glucose. By binding LCFA-CoA,  ACBP removes this end-product inhibition to 
stimulate Acac (10). Likewise, increased serum levels of LCFAs resulting in high 
intracellular LCFA-CoAs are deleterious to multiple cell functions and are associated 
with diabetes and obesity (10, 14). Again, by binding and reducing the unbound levels of  
LCFA-CoAs, ACBP plays important roles not only in normal regulation of LCFA-CoA 
________ 
This thesis follows the style of Lipids. 
*Reprinted with permission from “Acyl CoA Binding Protein (ACBP) Gene Ablation Induces Pre-
Implantation Emryonic Lethality in Mice” by Landrock D., Atshaves B.P., McIntosh A.L., Landrock K.K., 
Schroeder F., Kier A.B., 2010. Lipids, 45, 567-580, Copyright 2010 by Springer. 
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transport, metabolism, signaling, vesicular trafficking, and nuclear regulation, but also in 
opposing the deleterious effects of elevated intracellular LCFA-CoA levels (10, 14).  
The physiological relevance of these findings is supported mainly by studies of ACBP 
overexpression in yeast, mice, rats, and plants (Arabidopsis) (15-17). In vivo, pancreatic 
insulin secretion is affected by LCFA-CoA and ACBP levels as well as by glucose (14, 
18, 19). ACBP overexpressing rats fed a medium chain fatty acid-rich diet exhibited 
improved glucose tolerance and lower serum insulin levels (17). A single nucleotide 
polymorphism in the promoter region of the human ACBP gene is associated with 
reduced risk of type 2 diabetes in two German study populations—likely due to 
increased transcriptional activity of ACBP (20). 
Hypothesis    
While the above findings suggest that loss of ACBP could result in major disruptions of 
normal phenotype and possible lethality, the available evidence to date is unclear. While 
deletion of the ACBP gene in yeast results in a slower growing phenotype, the yeast 
subsequently adapt to a faster growing phenotype (21). A conditional ACBP inhibition 
knock-down in yeast alters lipids, membranes, and vesicle accumulation, but is not lethal 
(21). Although disruption of the 10 kDa ACBP gene in the plant Arabidopsis is not 
lethal, Arabidopsis expresses at least 5 additional ACBP genes that also bind LCFA-
CoA—likely compensating for the loss of the 10 kDa ACBP6 (22, 23). In contrast to 
plants, mice and humans have only a single ACBP encoding gene (7, 24). Treatment of 
mouse 3T3-L1 adipocytes with ACBP antisense RNA inhibits differentiation (25), while 
treatment of several human cell lines (HeLa, HepG2, Chang) with small interference 
3 
RNAi results in lethality (26). However, because transformed cells are often deficient in 
the other LCFA-CoA binding proteins (1, 27-29) it is difficult on this basis alone to 
predict if ACBP is an essential protein in mammals. 
Purpose of Study    
The purpose of the present investigation was to resolve whether ACBP is an essential 
protein in a mammalian system by ablating ACBP gene function by homologous 
recombination in mice. The data show that loss of ACBP resulted in early 
preimplantation embryonic lethality by the 8-cell stage. The fact that ACBP is the first 
known intracellular lipid binding protein whose deletion results in embryonic lethality 
suggests its vital importance in mammals.     
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MATERIALS AND METHODS* 
Construct Preparation 
A BAC clone containing the ACBP sequence was obtained from the BACPAC Resource 
Center (Oakland, CA). Restriction enzymes were from Invitrogen (Carlsbad, CA) while 
DNA purification kits (Miniprep, Maxiprep, Agarose Gel Extraction kits, PCR 
purification kits) were from Qiagen (Valencia, CA). Prime-A-Gene labeling was from 
Promega (Madison, WI), and oligonucleotides from Integrated DNA Technologies 
(Coralville, IA). Embryonic stem cells: The 129S6-derived embryonic stem (ES) cell 
line W4 was from Taconic Inc. (Hudson, NY) while primary mouse embryonic 
fibroblasts (PMEF) were from Specialty Media (Phillipsburg, NJ). Fetal bovine serum 
was from Summit Biotechnology (Fort Collins, CO) while cell culture media and 
components (non-essential amino acids, penicillin, streptomycin, L-glutamine, G418,  
sodium pyruvate) were from Invitrogen (Carlsbad, CA). Leukemia inhibitory factor 
(LIF, ESGRO®) was from Chemicon (Temecula, CA). Embryo isolations: M2 and M16 
media, Pregnant Mare Serum Gonadotropin (PMSG), human chorionic gonadotropin 
(hCG), mineral oil and hyaluronidase were from Sigma-Aldrich (St. Louis, MO), 
Potasium Simplex Optimized Medium (KSOM) was from Millipore (Billerica, MA), and 
ES cell injection needles and blastocyst holding capillaries were from Eppendorf 
(Hamburg, Germany).  
________ 
*Reprinted with permission from “Acyl CoA Binding Protein (ACBP) Gene Ablation Induces Pre-
Implantation Emryonic Lethality in Mice” by Landrock D., Atshaves B.P., McIntosh A.L., Landrock K.K., 
Schroeder F., Kier A.B., 2010. Lipids, 45, 567-580, Copyright 2010 by Springer. 
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Animals 
All animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Texas A&M University. Male and female inbred C57BL/6NCr 
mice were from the National Cancer Institute (Frederick Cancer Research and 
Developmental Center, Maryland). ACBP genetically-engineered mice were generated 
as described in the section below.  All mice were maintained in microisolators, with a 12 
hour light/dark cycle in a temperature-controlled facility (25°C), access to standard 
commercial rodent chow (Teklad®, Harlan, Indianapolis, IN) and water ad libitum. Mice 
were monitored by the presence of sentinels quarterly and found negative for all known 
mouse pathogens.  
Generation of ACBP Gene Ablated Mice 
The mouse ACBP null targeting construct was designed to replace the N-terminal 
promoter region (including the known SREBP and PPARγ response elements), exon 1, 
intron 1, exon 2, and part of intron 2 of the ACBP gene with a neomycin cassette. The 
following two overlapping genomic DNA fragments from mouse clone RP23-430P22 
(BACPAC Resources Center, BPRC, Oakland, CA) were used to form the backbone of 
the ACBP gene targeting construct: a 7 kbp XhoI clone containing the promoter region, 
exon 1, exon 2, and the surrounding intronic sequences of the ACBP gene and a 7 kbp 
HindIII clone containing exons 1 through 3 and surrounding intronic sequences. Mouse 
ACBP genomic sequences were confirmed by extensive restriction mapping and DNA 
sequencing. The 5’ arm of homology was generated by ligating a 4.2 kbp XhoI/SmaI 
fragment from the 7 kbp XhoI clone into pBlueScript-SK (pBS-SK; Stratagene, La Jolla, 
6 
CA). An intermediate targeting construct consisting of the neomycin resistance marker 
and a 3.9 kbp XhoI/HindIII fragment from the 7 kbp HindIII clone was generated by 
ligating the neo cassette from a pPGK-Neo vector to the 3.9 kbp XhoI/HindIII fragment. 
Ligating the 5’ homology arm with the intermediate targeting construct pre-digested 
with SmaI completed the targeting construct. Once complete, the targeting construct was 
linearized with NotI and electroporated into the W4 ES cell line maintained on a PMEF 
feeder layer. Disruption of the ACBP gene was generated through homologous 
recombination. After selection with G418, DNA was isolated from surviving clones, 
digested with HindIII, and screened by Southern blotting analysis following standard 
protocols. Using a 760 bp 3’ probe, targeted clones were identified by Southern blotting 
with the presence of a 4.5 kbp band while absence of the targeting construct was 
indicated by a 7 kbp band. Four positive clones were expanded and injected into 
C57BL/6NCr blastocysts to create chimeric mice following standard procedures. Four 
male chimeras from two separate ES cell clones were identified by coat color and bred to 
C57BL/6NCr females to determine germ-line transmission of the targeted allele. Tail 
DNA from the chimera/wild-type backcross F1 offspring were initially screened with 
Southern blotting by standard procedures to verify germline transmission. Subsequent 
generations of heterozygote/heterozygote and wild-type crosses (for PCR controls) were 
genotyped by PCR, with the following primer sets: forward primer (ACBP-anchor, 5’-
CAA CCT CTG CCA TCA CCT ATT C-3’); reverse primer wild type (ACBP-wt, 5’-
TTC TCT GTA TAG CTC TGG CTG G-3’) and reverse primer gene ablation (ACBP-
ko, 5’-GGT GGC TAC CCG TGA TAT TG-3’), for 35 cycles with an annealing 
7 
temperature set at 58°C.  
Isolation of Pre- and Postimplantation Stage Embryos 
ACBP heterozygotes or wild-type (control) females were paired overnight with ACBP 
heterozygotes and wild-type males respectively and checked for the presence of a 
copulation plug the next morning. The day of the copulation plug was designated 0.5 
post coitum (dpc). Females were humanely euthanized by cervical dislocation 
immediately prior to embryo isolation. Postimplantation embryos were obtained by 
dissecting the uterus at 9.5, 11.5, 14.5 and 17.5 dpc. These embryos were freed of any 
extra-embryonic tissue and then prepared for PCR analysis. Preimplantation embryos 
were obtained by flushing the oviducts or uterus, depending upon the time point. One-
cell and two-cell (cleavage) oocytes were isolated from the oviducts the same morning 
of the copulation plug (0.5 dpc) and the following morning (1.5 dpc), respectively. 
Eight-cell (morula) stage embryos were isolated from the oviduct on the third day (2.5 
dpc) and blastocysts were obtained by flushing the uterus on the fourth day (3.5 dpc). 
Hepes-buffered M2 medium was used to flush and handle all embryos, and KSOM 
under mineral oil was used for up to 6 days for in vitro culture of all preimplantation 
embryos at 37°C, 5% CO2. One-cell stage embryos were treated with 1mg/ml of 
hyaluronidase and subsequently rinsed 5-10 times in sterile M2 medium to remove 
cumulus cells. The development and morphology of preimplantation stages were 
monitored by visualizing the embryos with an inverted phase contrast microscope 
(Nikon Diaphoto 300, Nikon, Tokyo, Japan) at 12-hour intervals after oocyte collection. 
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Genotyping of Pre- and Postimplantation Embryos 
Genotyping of individual preimplantation embryos was performed using the 
REDExtract-N-Amp Tissue PCR kit (Sigma-Aldrich, St. Louis, MO) according to the 
manufacturer’s protocol. Genomic DNA from postimplantation embryos was obtained 
by digesting a small section of tail in 500µl of lysis buffer (10mM Tris-HCl, 1mM 
EDTA, 300mM Na acetate, 1% SDS, 0.2mg/ml proteinase K) for 6 hours at 55ºC, 
followed by 20 minutes at 95ºC to inactivate the proteinase K. The lysate was used 
directly for PCR genotyping. The same PCR primer sets to genotype embryos were used 
as with the live offspring. Initial embryo genotyping was performed on embryos isolated 
from the F2 intercross heterozygote generation. All embryos genotyped for real-time 
reverse transcriptase polymerase chain reaction (Q-rtPCR) were from the N6 
heterozygote intercross generation or greater.  
Quantitative (Real-Time) Reverse Transcriptase PCR 
Q-rtPCR was performed on total RNA from 2.5 dpc embryos isolated and purified using 
RNeasy Micro kit (Qiagen,Valencia, CA) according to manufacturer’s protocol. 
Expression patterns were analyzed with an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems, Foster City, CA) using TaqMan® One Step PCR Master 
Mix Reagent kit, gene specific TaqMan® PCR probes and primers, and the following 
thermal cycler protocol: 48°C for 30 minutes for reverse transcription prior to 
amplification, 95°C for 10 minutes before the first cycle, 95°C for 15 seconds, and 60°C 
for 1 minute, repeated 60 times. For other specific probes and primers, TaqMan® Gene 
Expression Assay products for mouse peroxisome proliferator-activated receptor-α 
9 
(Pparα, Mm00440939_m1); Sterol carrier Protein 2 (Scp-2, Mm01257982_m1); m-
calpain (Capn2, Mm00486669_m1), and Custom-TaqMan®-Assay products Sterol 
Carrier Protein-x (Scp-x, SEQ_SCPX-EX23); Acyl CoA Binding Protein (Acbp, 
SEQ_ACBP). Measurements were performed in duplicate and analyzed with ABI 
PRISM 7000 SDS software to determine the threshold cycle (CT) from each well. Primer 
concentrations and cycle number were optimized to ensure that reactions were analyzed 
in the linear phase of amplification. To analyze the Q-rtPCR data, mRNA expression of 
Pparα, Scp-2, Scp-x, and Capn2 in homozygous null preimplantation embryos were 
normalized to a housekeeping gene (18S rRNA) and were made relative to the control 
wild-type preimplantation embryos and were calculated using the comparative 2-ΔΔCT 
method (30) where ΔΔCT = [CT of target gene – CT of 18s]ACBP-null embryos – [CT of target 
gene – CT of 18s]wild type embryos as described in User Bulletin 2, ABI PRISM 7000 SDS. 
Calculation of Free, Unbound Long Chain Fatty Acyl CoA 
Because high levels of free LCFA-CoA may inappropriately affect proteins or act as 
potent detergents (31, 32), the effect of ACBP level on free unbound LCFA-CoA 
concentration was modeled as a function of ACBP versus total LCFA-CoAs. Calculation 
of free and unbound LCFA-CoA as a function of total LCFA-CoA and ACBP 
concentration was performed using Eq. 1,   
   [ ] [ ] [ ][ ] [ ]FFd
F
T CCK
CPC +⎟⎟⎠
⎞
⎜⎜⎝
⎛
+=                                        Eq. 1 
where CT and CF is the total and free acyl CoA concentration respectively, P is the ACBP 
10 
concentration, and Kd is the dissociation constant of ACBP. CF was plotted vs. CT. Since 
the affinity of ACBP’s single binding site for LCFA-CoAs as previously determined by 
fluorescence, microcalorimetry, and mass spectrometery was in a narrow range (Kd = 7-12 
nM) (33-35), an average Kd = 9.5 nM was used in this calculation. The range of LCFA-
CoA concentration used in these calculations was based on the known range reported for 
all tissues, i.e. 5-150 μM (31, 32). 
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RESULTS* 
Generation of ACBP Gene Ablated Mice 
The strategy for generation of a mouse ACBP null targeting construct was dictated by 
the biological activity of ACBP proteolytic fragments as well as the unique nature of the 
ACBP gene itself. For example, the N-terminal region of ACBP is the precursor of two 
major biologically active peptides active in lipid metabolism, signaling, and insulin 
secretion (19, 36, 37). In addition, alternative splicing in the mouse ACBP gene results 
in transcription of two mRNA transcripts encoding proteins of 86 and 135 amino acids, 
respectively (7). Therefore, the mouse ACBP null targeting construct was designed to 
replace the N-terminal promoter region (including the known SREBP and PPARα 
response elements), exon 1, intron 1, exon 2, and part of intron 2 of the ACBP gene with 
a neomycin cassette (Fig. 1A). Chimeric ACBP gene ablated mice were developed using 
this construct as described in Methods. The offspring from chimera/wild-type 
backcrosses were genotyped by Southern blotting using a 3’ probe constructed from 
sequence immediately after the disrupted locus (horizontal solid bar after exon 3). 
Southern blotting of HindIII-digested DNA revealed wild-type (7 kB) and targeted 
heterozygous (4.5 kB) DNA (Fig. 1B). A PCR screen from tail clips was then developed 
(Fig. 1C), using the two primer sets as described in Methods, for genotyping all other 
offspring.  
 
________ 
*Reprinted with permission from “Acyl CoA Binding Protein (ACBP) Gene Ablation Induces Pre-
Implantation Emryonic Lethality in Mice” by Landrock D., Atshaves B.P., McIntosh A.L., Landrock K.K., 
Schroeder F., Kier A.B., 2010. Lipids, 45, 567-580, Copyright 2010 by Springer. 
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Fig. 1. Construct Design and Screening of ACBP Gene-Ablated Mice. (A) The 
targeting construct, wild-type ACBP locus and targeted locus after homologous 
recombination. Two lower diagrams show the wild-type locus and targeted ACBP locus 
with expected HindIII fragment sizes with the indicated probe (solid bar after exon 3). (B) 
Southern blotting analysis of genomic DNA from F1 offspring of chimera/wild-type 
backcrosses using the 3’ probe just outside of the disrupted ACBP locus. (C) PCR analysis 
of genomic DNA from offspring of heterozygote/heterozygote intercrosses using 2 primer 
sets. (-/+) = ACBP heterozygotes; (+/+) = wild-type counterparts. 
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ACBP Heterozygous Mice are Phenotypically Normal 
Wild type and heterozygous mice were indistinguishable with respect to visual 
appearance, postimplantation embryonic weight (Fig. 2A), body weight at weaning (not 
shown), adult body weight (Fig. 2B), and fertility (not shown).  
The ACBP Null Mutation is Embryonically Lethal 
The F1 ACBP heterozygotes were intercrossed to produce ACBP null offspring. Instead 
of the expected Mendelian 1:2:1 ratio of  25% wild-type, 50% heterozygous, and 25% 
null ACBP mice, examination of 171 total F2 offspring from 21 litters yielded no 
homozygous null ACBP pups (Fig. 3). The remaining greater than 2:1 ratio of 
heterozygous to wild-type mice was consistent with the absence of adverse effects of the 
mutant allele in the heterozygotes (Fig. 3), and average litter size was within normal 
range of a hybrid B6:129 strain (D. Landrock, unpublished data). Pregnant females were 
carefully monitored until the day of parturition. No evidence for increased neonatal 
lethality or cannibalization was noted. Taken together, these data indicated a potential 
embryonic lethality. 
 
 
 
 
 
 
 
14 
 
 
 
 
Fig. 2. Body Weights of Heterozygous (-/+) and Wild-Type (+/+) Postimplantation 
Embryo Littermates and Adult Counterparts. Full body weights of wild-type (A, solid 
bars) and ACBP heterozygous (A, cross-hatched bars) postimplantation embryos are 
indicated at the E22 (14.5 dpc) and E25 (17.5 dpc) stages.  Body weights of adult wild-
type (B, solid bars) and ACBP heterozygous ACBP (B, cross-hatched bars) male and 
female counterparts. There were no significant differences in any of the groups. 
15 
 
 
Fig. 3. Genotypes of Live F2 Offspring from ACBP Heterozygote Male and Female 
F1 Intercrosses. From 21 intercross litters of mice, no homozygous ACBP null offspring 
were detected. ACBP heterozygotes constituted 73.6% (126) of offspring (cross-hatched 
bar). Wild-type mice represented 26.4% (45) of offspring (solid bar). (-/-) = homozygous 
ACBP null; (-/+) = ACBP heterozygotes; (+/+) = wild-type mice from the same litters. 
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Genotypes of Postimplantation Embryos 
To determine if ACBP gene ablation resulted from a postimplantation embryonic 
lethality, the genotypes of postimplantation F2 embryos from F1 ACBP 
heterozygote/heterozygote intercrosses were determined. Of the 35 postimplantation 
embryos isolated, no ACBP homozygous null embryos were recovered 9.5 dpc (E15, 9 
total, Fig. 4A), 11.5 dpc (E19, 8 total, Fig. 4B), 14.5 dpc (E22, 9 total, Fig. 4C), and 17.5 
dpc (E25, 9 total embryos, Fig. 4D). No evident indicators of resorbed embryos were 
found during dissection. Thus, ACBP null embryos never formed, or died prior to or 
very shortly after implantation.   
Genotypes of Preimplantation Embryos 
To determine if ACBP null mice resulted in a preimplantation embryonic lethality, the 
genotypes of 310 of 510 preimplantation F2 embryos from F1 ACBP heterozygote 
intercrosses were determined at the 2-cell (oocyte), ~8-cell (morula), and ~32-cell 
(blastocyst) stages. At the oocyte stage, the amount of DNA recovered for PCR was 
minimal; thus it was not possible to identify the genotype of all oocytes at this stage. Of 
over 200 oocytes recovered, 36 were clearly identified as to genotype, of which 4 were 
the homozygous null ACBP genotype (Table 1). As shown by representative light 
microscopic images, the null ACBP oocytes (Fig. 5A) did not differ in appearance from 
wild-type oocytes (Fig. 5E).  Of 146 morulae recovered, 17 were the ACBP homozygous 
null genotype (Table 1). Similarly, light microscopy showed that the ACBP null morulae 
(Fig. 5B) did not differ significantly in appearance from wild-type (Fig. 5F). In contrast, 
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while 128 blastocysts were recovered and genotyped, none were the ACBP null 
genotype (Table 1). Furthermore, light microscopy showed that some blastocysts 
appeared to be undergoing degeneration (Fig. 5D), while the majority appeared normal 
(Fig. 5H). Due to DNA degradation, it was not possible to definitively genotype the 
degenerating blastocysts. These dead/dying blastocysts most likely represented ACBP 
homozygous null embryos. Thus, ACBP gene ablation resulted in early preimplantation 
embryonic lethality beginning by the 2.5 dpc morula (8-cell) stage, and none were viable 
by the 3.5 dpc blastocyst (~32-cell) stage. 
 
 
 
Table 1. Genotype Distribution Among Preimplantation Embryos from  
Heterozygote F1 Intercrosses. 
 
Embryo Genotype 
(-/-) (-/+) (+/+) Stage Age (dpc) Total % Total % Total % 
Blastocyst 
(~32-cell) 3.5 0 0 81 63.3 47 36.7 
Morula 
(~8-cell) 2.5 17 11.6 99 67.8 30 20.6 
Oocyte  
(2-cell) 1.5 4 11.1 22 61.1 10 27.8 
Genotyping was performed by PCR (dpc = days post coitum). 
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Fig. 4. Genotypes of Postimplantation Embryos from ACBP Heterozygote 
Intercrosses. Embryos were examined at four stages of development: (A) E15 (9.5 dpc, 9 
total embryos); (B) E19 (11.5 dpc, 8 total embryos); (C) E22 (14.5 dpc, 9 total embryos); 
and (D) E25 (17.5 dpc, 9 total embryos). (-/-) = homozygous ACBP null (open bars); (-/+) 
= ACBP heterozygotes (cross-hatched bar); (+/+) = wild-type mice from the same litters 
(black bar). 
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Fig. 5. Preimplantation Development of Homozygous ACBP Null and Wild-Type 
Embryos. E1 (0.5 dpc) oocytes from ACBP heterozygote intercrosses were isolated, 
cultured in KSOM medium, and photographed every 12h to monitor their development. 
At the indicated times, each embryo was genotyped by PCR. Panels A-D show 
representative homozygous null ACBP preimplantation embryos, while panels E-H 
show representative wild-type embryos at the same stages. Preimplantation embryos at 
the E1 early oocyte stage (0.5 dpc, panels A, E)) have arrows pointing to the two 
pronuclei, indicating fertilization; Panels B, F indicate the E2 oocyte cleavage stage (1.5 
dpc); panels C, G, the E3 morula stage (2.5 dpc); and panels D, H the E5 blastocyst stage 
(3.5 dpc). Degeneration of several embryos at the blastocyst stage likely represent 
dead/dying ACBP homozygous null embryos (D); DNA isolation was attempted 
numerous times but was too degenerated for definitive genotyping. (-/-) = homozygous 
ACBP null; (-/+) = ACBP heterozygotes; (+/+) = wild-type mice. 
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Q-rtPCR of ACBP in Preimplantation Embryos 
To determine if the lethality was associated with total absence of ACBP transcription, 
2.5 and 3.0 dpc embryos from ACBP heterozygote intercrosses were examined by Q-
rtPCR. The ACBP transcript was detected in wild-type and heterozygous embryos at the 
2.5 dpc morula (Fig. 6A, 6B) and 3.0 dpc stage (Fig. 6B) just prior to blastocyst 
formation. In contrast, no Acbp was detected in the morula 2.5 dpc stage of ACBP null 
embryos (Fig. 6A, 6B). Detection of Acbp in 3 dpc ACBP null embryos was not possible 
because no ACBP null embryos were found by this late morula/early blastocyst stage 
(Fig. 6B, ∞).  Thus, the ACBP transcript was absent in the ACBP homozygous null 2.5 
dpc stage morula, preceding the embryonic lethality by the blastocyst 3-3.5 dpc stage 
(Fig. 5D, Fig. 6B). Western blotting to determine presence of the ACBP protein in the 
null morulae was not possible due to the limited amount of material present at this early 
stage of development. 
Concomitant Upregulation of Other Long Chain Fatty Acyl CoA Binding Proteins 
Since ACBP gene ablation was not lethal at the morula 2.5 dpc stage, the possibility that 
loss of ACBP was temporarily compensated for at least in part by upregulation of 
another cytosolic LCFA-CoA binding protein was examined. Sterol carrier protein-2 
(SCP-2) and sterol carrier protein-x (SCP-x) bind LCFA-CoAs with similar affinities as 
ACBP (8, 38);  their ablation is not lethal (39-41); and they are expressed as early as the 
zygote 1-cell stage, slightly earlier than ACBP at the 2-cell stage (Fig. 7A). SCP-2 
expression in null ACBP 2.5 dpc morulae was upregulated 10-fold (Fig. 6A).  Likewise, 
expression of Scp-x in ACBP null morulas (2.5 dpc) was upregulated over 50-fold  (Fig. 
22 
6A). These data suggest that significant upregulation of SCP-2 and SCP-x may indicate 
an attempt to compensate for the loss of ACBP to maintain viability.  
 The possibility that ACBP gene ablation may result in compensatory 
upregulation of the nuclear peroxisome proliferator-activated receptor-α (PPARα) was 
also investigated. PPARα exhibits high affinity for LCFA-CoAs (12, 13) and PPARα 
coactivator recruitment and transcriptional activity are regulated by both LCFA-CoAs 
and ACBP (12, 13, 42, 43). Furthermore, expression of the PPARα transcript occurred 
by the zygote (1-cell) stage, thereby preceding that appearance of ACBP which normally 
occurs at the oocyte cleavage (2-cell) stage (Fig. 7A). However, ACBP gene ablation did 
not significantly alter the expression of Pparα at the morula (2.5 dpc) stage. Thus, 
viability of very early preimplantation ACBP null embryos was not associated with 
concomitant upregulation of PPARα. 
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Fig. 6. Expression of ACBP and Other Key Long Chain Fatty Acyl CoA Binding 
Proteins in Preimplantation Embryos. Embryos were isolated from ACBP heterozygote 
intercross mice, and levels of ACBP, sterol carrier protein-2 (SCP-2), sterol carrier 
protein-x (SCP-x), peroxisome proliferator-activated receptor-α (PPARα), and m-calpain 
were determined by Q-rtPCR as described in Methods. (A) Acbp, Scp-2, Scp-x, and Pparα 
expression was determined in homozygous ACBP null embryos (open bars) and wild-type 
embryos (solid bars) at the 2.5 dpc morula stage (E3). Values represent means ± SEM; * = 
p < 0.05 between ACBP null and wild-type embryo; *** = p < 0.0001 between ACBP null 
and wild-type embryo. (B) Acbp and m-calpain expression was determined in 
homozygous null ACBP, heterozygous ACBP, and wild-type ACBP embryos at the 
morula (E3, 2.5 dpc) and early blastocyst (E4, 3.0 dpc) stages. (∞) indicates no live 
embryos found. (-/-) = homozygous ACBP null; (-/+) = ACBP heterozygous; (+/+) = wild-
type embryos. 
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Since ACBP is a potent activator of m-calpain, a protease involved in apoptosis 
(44), the possibility that m-calpain transcript (Capn2) is expressed at an early 
preimplantation embryonic stage was investigated. Capn2 was not expressed in the 
morula (2.5 dpc) embryonic stage of ACBP null, heterozygote, or wild-type embryos 
(Fig. 6B). Since Capn2 was not detected until 3.0 dpc and no ACBP null preimplantation 
embryos were detected by that stage, embryonic lethality at >2.5 dpc was not associated 
with ACBP activation of m-calpain.    
Effect on Unbound Free Long Chain Fatty Acyl CoA (LCFA-CoA) Concentration 
LCFA-CoAs are potent regulators (Kis as low as 50 nM) of many enzymes, transporters, 
and receptors involved in lipid and glucose metabolism (Table 2). Since determination of 
LCFA-CoA and ACBP protein concentrations would require more material than is 
present in these early stage embryos to be detectable, the effect of ACBP on the free 
unbound LCFA-CoA concentration was modeled over the known physiological range of 
LCFA-CoAs and ACBP concentrations in mammalian tissues. At the upper range of 
physiological ACBP concentration (50 μM), ACBP very effectively buffered the 
unbound LCFA-CoA concentrations over a relatively broad range (Fig. 8A). The 
unbound LCFA-CoA concentration was <50 nM up to 40 μM total LCFA-CoA (Fig. 
8B). In contrast, estimated lower physiological ACBP concentration (6 μM) was 
relatively ineffective in buffering the unbound LCFA-CoA level (Fig. 8A), which was  
> 50 nM even at 10 μM total LCFA-CoA (Fig. 8B). Taken together, these data suggest 
that the loss of ACBP would likely result in significantly increased free unbound LCFA-
25 
CoA levels within the null embryo cells, which in turn would adversely affect many 
proteins, enzymes, and receptors involved in both lipid and glucose metabolism.  
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Fig. 7. Embryonic Development Timeline of the First Detected Expression of Key 
Fatty Acid Binding Proteins (A), Nuclear Receptors (A), and Enzymes (B) Involved 
in Lipid and Glucose Metabolism and Regulated by Low Levels of LCFA-CoAs. 
Transcript abbreviations encoding the respective proteins: Acbp, ACBP; Scp-x, SCP-x; 
Scp-2, SCP-2; Fabp1, L-FABP; Fabp2, I-FABP; Fabp3, H-FABP; Fabp4, A-FABP; 
Fabp5, E-FABP;  Fabp7, B-FABP; Ppara, PPARα; Pparg, PPARγ; Thra, thyroid 
hormone receptor-α; Thrb, thyroid hormone receptor-β; Capn2, m-calpain; Acaca, acetyl 
CoA carboxylase A; Acacb, acetyl CoA carboxylase B; Prkaa2, AMP-activated kinase 
(protein kinase, AMP-activated, alpha 2 catalytic subunit); Hmgcr, HMG-CoA 
reductase; Slc25a4, solute carrier family 25 member 4 (mitochondrial carrier, adenine 
nucleotide translocator); Slc25a5, solute carrier family 25 member 4 (mitochondrial 
carrier, adenine nucleotide translocator); Slc25a13, solute carrier family 25 member 13 
(mitochondrial carrier, adenine nucleotide translocator); Slc25a20, solute carrier family 
25 member 20 (mitochondrial carrier, adenine nucleotide translocator); Slc25a31, solute 
carrier family 25 member 31 (mitochondrial carrier, adenine nucleotide translocator); 
Atp1b1, Na+,K+-ATPase (ATPase, Na+/K+ transporting beta 1 polypeptide); Atp2a2, 
Ca++-ATPase (endoplasmic reticulum); Hk1, hexokinase 1; Hk2, hexokinase ; Hk3, 
hexokinase 3; Gck, glucokinase (hexokinase 4); Acadl, long chain acyl CoA 
dehydrogenase; and Lipe, hormone sensitive lipase. Expression profiles were established 
by Q-rtPCR(*), or inferred from Expressed Sequence Tag (EST) counts, from  the NCBI 
UniGene database, October 2009, http://www.ncbi.nlm.nih.gov/unigene). 
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Table 2.  Regulation of Key Enzymes/Receptors in Lipid and Glucose Metabolism by  
LCFA-CoAs and ACBP. 
 
 
Gene 
 
Protein 
Effect of 
LCFA-CoA
Ki 
(μM)
Effect of 
ACBP 
 
References
Fatty Acid Synthesis 
Acaca Acetyl CoA carboxylase Inhibit 0.05 Stimulate (31) 
 Mitchondrial acyl CoA 
synthetase 
Inhibit 4  Stimulate (45) 
Fatty Acid and Cholesterol Synthesis 
Prkaa2 AMP-activated kinase kinase 
Stimulate nM      ? (46) 
Cholesterol Synthesis 
Hmgcr HMG-CoA reductase Inhibit <2      ? (47) 
Fatty Acid β-Oxidation 
Cpt1 Carnitine palmitoyl transferase I 
Inhibit 20 Stimulate (48) 
Acadl Long chain acyl CoA dehydrogenase 
Inhibit 0.2      ? (49) 
Cholesteryl ester/Triacyglyceride Hydrolysis 
Lipe Hormone sensitive lipase 
Inhibit 0.5      ? (50) 
Glucose Metabolism 
Gck (Hk4) Glucokinase Inhibit 0.5      ? (51) 
Gapdh 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
Inhibit 0.5      ? (52) 
Slc25a Adenine nucleotide translocase 
Inhibit <1 Stimulate (31) 
Receptors, Transporters, and Processes 
Thr Nuclear thyroid hormone receptor 
Inhibit 0.1      ? (53) 
Atp1b1 Na
+,K+-ATPase (plasma 
membrane) 
Stimulate     3      ? (54) 
Atp2a2 Ca
++-ATPase 
(endoplasmic reticulum)
Stimulate <0.5      ? (55) 
 Vesicular transport 
(Golgi) 
Stimulate       ? (56) 
 
 
29 
 
 
Fig. 8. Modeling the Effect of ACBP Ligand Binding on Free LCFA-CoA 
Concentration in Embryos. Free LCFA-CoA concentrations were calculated at a 
constant ACBP level in the presence of increasing total LCFA-CoA level as described in 
the Methods, using the average dissociation constant of ACBP, Kd = 9.6 nM. Panel A, 
amount of free unbound LCFA-CoA as a function of total available LCFA-CoA in the 
range of 1-100 μM was plotted for embryos containing physiologically high (50 μM) 
and low (6 μM) ACBP.  Panel B, Vertical bar graph of the effect of physiologically high 
(50 μM) and low (6 μM) ACBP concentration on amount of total LCFA-CoAs of 10, 20, 
40, and 80 μM. 
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SUMMARY AND DISCUSSION* 
Although long chain fatty acyl CoAs (LCFA-CoAs) are well known intermediates in 
fatty acid metabolism, they are also potent metabolic regulators of multiple 
enzymes/proteins involved in fatty acid and glucose metabolism (1, 10, 14, 57). While 
physiologic tissue total LCFA-CoA levels are in the 5-150 μM range (1, 10, 14, 57), 
even surprisingly low levels (50-500 nM) of free unbound LCFA-CoAs inhibit a broad 
variety of enzymes, transporters, signaling receptors, and nuclear receptors involved in 
key cellular processes such as fatty acid and cholesterol synthesis, transcription of genes 
in lipid metabolism, mitochondrial fatty acid oxidation, and glucose metabolism  (Table 
2). The respective Kis by LCFA-CoA for many of these proteins are as much as 3,000-
fold lower than the range of total LCFA-CoA levels in tissues (1, 10, 14, 57). Since these 
proteins are known to be active in tissues, the actual unbound free LCFA-CoA levels are 
much lower (10-20 nM) due to buffering by intracellular LCFA-CoA binding proteins–
especially ACBP (reviewed in 1, 10, 14, 57). The present investigation determining the 
effect of ACBP gene ablation on the phenotype of mice yielded the following insights: 
ACBP - First Embryonic Lethal Mutation of the LCFA-CoA Binding Proteins 
First, single gene deletion of ACBP is the first known embryonic lethal mutation of any 
of the intracellular LCFA-CoA binding protein families.  At least three families of  
soluble lipid binding proteins appear to buffer cytoplasmic LCFA-CoA levels by binding 
________ 
*Reprinted with permission from “Acyl CoA Binding Protein (ACBP) Gene Ablation Induces Pre-
Implantation Emryonic Lethality in Mice” by Landrock D., Atshaves B.P., McIntosh A.L., Landrock K.K., 
Schroeder F., Kier A.B., 2010. Lipids, 45, 567-580, Copyright 2010 by Springer. 
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LCFA-CoAs with high affinity in  the order: acyl CoA binding protein (ACBP) (1, 10, 
14, 57)  >  sterol carrier proteins [sterol carrier protein-2 (SCP-2), sterol carrier protein-x 
(SCP-x)] (58) > select fatty acid binding proteins [FABP1 (L-FABP) >> FABP7, 
FABP2, FABP3 (B-FABP, I-FABP, H-FABP)] (59-61). Of these LCFA-CoA binding 
proteins only ACBP, SCP-2/SCP-x, and FABP3 are expressed in preimplantation 
embryos (Figure 7.).  However, FABP3 (H-FABP) binds LCFA-CoA more weakly than 
FABP1 (L-FABP)—a protein not expressed in preimplantation embryos (Figure 7.) (59, 
60). Thus, redundancy in LCFA-CoA binding proteins is much more limited in pre-
implantation embryos than in mature tissues. This would suggest that loss of one of the 
lower affinity LCFA-CoA binding proteins would not likely be lethal, and to date 
lethality has not been observed upon gene ablation of several members of the large 
FABP protein family, including: Fabp1 (liver L-FABP), Fabp2 (intestinal I-FABP), 
Fabp3 (heart H-FABP), Fabp4 (adipocyte A-FABP), Fabp5 (keratinocyte K-FABP), and 
Fapb7 (brain B-FABP) (62-64). Likewise, ablation of SCP-2 and SCP-x is not lethal (40, 
41, 65). Even intercrossing of L-FABP null mice and SCP-2/SCP-x null mice does not 
result in lethality (66). Thus, embryonic lethality in mice ablated for the single gene 
encoding ACBP is unique among the multiple LCFA-CoA binding proteins known to 
exist in cytoplasm of mammalian tissues.   
ACBP Gene Ablation–Induced Lethality at Very Early Preimplantation Stages 
Second, the ACBP gene ablation-induced embryonic lethality at very early 
preimplantation stages where the embryo is not well differentiated was consistent with 
that observed in highly undifferentiated tumor cells wherein ACBP is reduced by 
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treatment with ACBP antisense RNA.  Transformed cell lines express ACBP, but have 
markedly reduced levels of other LCFA-CoA binding proteins (e.g. FABPs, SCP-
2/SCPx) (reviewed in 1, 27-29). Consequently, ACBP antisense RNA treatment of 
highly undifferentiated human transformed cell lines is lethal–likely due to loss of 
LCFA-CoA buffering capacity concomitant with loss of ACBP (3, 26). The fact that  
some apparently normal ACBP null embryos, albeit reduced in expected numbers, were 
still alive at the 1-8 cell preimplantation stages, but not later embryonic stages, was most 
likely due to the presence of  residual maternal ACBP protein. Although almost all 
maternal mRNA is degraded by the middle of the 2-cell stage (67, 68), maternal ACBP 
protein likely survives longer as indicated by the relatively long the t1/2 of ACBP protein 
in the range of 25-53 hours (67-69). Concomitant upregulation of two much less 
prevalent LCFA-CoA binding proteins (SCP-2 and SCP-x, primarily in peroxisomes)  
shown herein may have also facilitated survival at the morula (8 cell) stage but was 
insufficient to assure survival by the blastocyst (~32 cell, 3.5 dpc) stage. 
Lethality of ACBP Ablation Consistent With Deleterious Effects of LCFA-CoAs 
Third, the early preimplantation embryonic lethality in ACBP null mice was consistent 
with the importance of ACBP in preventing deleterious effects of LCFA-CoAs on 
sensitive enzymes involved in energy production and fatty acid biosynthesis. While fatty 
acids (primarily derived  from endogenous triglyceride) are the major energy source in 
unfertilized oocytes, thereafter very little energy is derived from fatty acids and 
intracellular triglyceride is maintained relatively constant (70). Since there is too little 
glycogen to sustain preimplantation embryos, especially that of the mouse, the 
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preimplantation embryo is heavily dependent on exogenous energy supply (70). 
Pyruvate and lactic acid in oviductal fluid represent the major carbon sources of mouse 
preimplantation embryos up to the 4 cell stage, while glucose serves this purpose 
thereafter (70-72). Acetyl CoA derived from these nutrients is oxidized to produce 
energy or is used as a substrate for the cytoplasmic enzyme acetyl CoA carboxylase 
(Acac) which catalyzes the rate limiting step in fatty acid biosynthesis for formation of 
membranes and longer term energy storage than can be accomplished by glycogen.  
Acetyl CoA carboxylase is exquisitely sensitive (Ki 50nM) to the presence of  even very 
low levels of LCFA-CoA (10).  As shown herein, loss of ACBP (the major high-affinity 
LCFA-CoA binding protein) is expected to eliminate most of the LCFA-CoA buffering 
capacity  because the other major LCFA-CoA binding protein (FABP1, i.e. L-FABP) is 
not induced until much later in development. Furthermore, LCFA-CoA binding proteins 
such as SCP-2 and SCP-x (present and concomitantly upregulated in ACBP null 
preimplantation embryos) are largely compartmentalized in peroxisomes and are present 
at much lower level (reviewed in 58). Since ACBP is thought to be the most effective of 
the LCFA-CoA binding proteins in buffering the unbound free LCFA-CoA 
concentration (10, 73), complete loss of ACBP would thus be expected to greatly 
increase unbound free LCFA-CoAs over that normally present in cells and tissues. 
ACBP Exhibits a Unique Role in Early Preimplantation Embryonic Development 
Fourth, ACBP exhibits a unique role in early preimplantation embryonic development as 
compared to the other intracellular LCFA-CoA binding proteins. Several other 
cytoplasmic LCFA-CoA binding proteins (FABPs 5, 4, and 3; SCP-2, SCP-x) are 
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expressed already by the zygote 1-cell to morula 8-cell stages (Fig. 7), but gene ablation 
of many of these proteins is not been lethal (40, 41, 62-65). ACBP is also known to enter 
the nucleus, bind nuclear receptors (PPARα, PPARγ), and regulate transcriptional 
activity of these receptors (11, 29, 74, 75). PPARα itself exhibits high affinity for and is 
regulated by LCFA-CoAs transported by ACBP (12, 13, 29). While PPARs α and γ are 
both present at the zygote one-cell stage (Fig. 7), ablation of PPARα is not lethal, and 
ablation of PPARγ is lethal but not until much later, i.e. the post-implantation E10 stage 
(76, 77). Taken together, these findings suggest that complete absence of ACBP may 
also dysregulate PPARs–nuclear transcription factors important in development as well 
as lipid and glucose metabolism (78).    
ACBP Is an Essential Protein in Mammals 
Finally, ACBP does not appear to be an essential protein in other eukaryotes since 
ACBP deletion results in the appearance of revertants (yeast) and likely compensation 
by 5 other ACBP genes in plants (Arabidopsis) (21-23, 79). In contrast, mice and 
humans have only a single ACBP encoding gene (7, 24), which may explain why ACBP 
single gene ablation in mice was lethal. 
Conclusion 
In summary, the studies presented herein addressed for the first time the role of ACBP 
single gene ablation on development in mice. ACBP gene ablation resulted in pre-
implantation embryonic lethality between the morula (8 cell) and blastocyst (32 cell) 
stages. Although several other cytosolic LCFA-CoA binding proteins are expressed at 
these early pre-implantation embryonic stages, ablation of these other cytosolic LCFA-
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CoA binding proteins is not lethal. Thus, ACBP represents the first discovered LCFA-
CoA binding protein whose ablation results in lethality. While the exact role of ACBP in 
normal preimplantation embryonic development remains to be identified, at least two 
general possibilities may be considered: (i) Since the high affinity of ACBP for LCFA-
CoAs results in highly effective buffering of total LCFA-CoAs to maintain unbound free 
LCFA-CoAs at low levels, loss of ACBP likely results in a significant increase of 
unbound free LCFA-CoA levels. The elevated unbound free LCFA-CoA levels would 
consequently inhibit highly LCFA-CoA sensitive enzymes (e.g. acetyl CoA carboxylase) 
required for normal glucose metabolism and fatty acid synthesis in these rapidly growing 
preimplantation embryos; (ii) Since ACBP normally interacts with and regulates several 
nuclear receptors (e.g. PPARs) present in early preimplantation embryos, loss of such 
interactions may result in abnormal transcriptional regulation of genes involved not only 
in lipid and glucose metabolism but also development. Both factors could contribute to 
the lethality observed in these early preimplantation ACBP null embryos. 
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